Medical Mycology - PowerPoint PPT Presentation

Loading...

PPT – Medical Mycology PowerPoint presentation | free to download - id: 16452e-NTgxZ



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Medical Mycology

Description:

Kingdom Fungi. Eukaryocytes. Ascomycota. Basidiomycota. Zygomycota. Mitosporic Fungi ... KINGDOM. CHARACTERISTIC. EXAMPLE. Monera. Prokaryocyte. Bacteria ... – PowerPoint PPT presentation

Number of Views:1333
Avg rating:3.0/5.0
Slides: 123
Provided by: arthurf
Category:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Medical Mycology


1
MEDICAL MYCOLOGY Arthur F. Di Salvo, MD Reno,
Nevada
2
(No Transcript)
3
(No Transcript)
4
Medical Mycology Outline
  • HOUR SUBJECT
  • Introduction, Actinomycetes
  • Yeasts, Dermatophytes
  • Filamentous Fungi, Dimorphic Fungi
  • Dimorphic Fungi
  • Opportunistic Fungi

5
OBJECTIVES
  • To impart sufficient basic science of the
    medically important fungi to assist you in
    diagnosing mycotic diseases.
  • To impart sufficient clinical knowledge
  • to raise your index of suspicion for mycotic
    diseases.

6
  • What is SAID is not HEARD
  • What is HEARD is not UNDERSTOOD
  • What is UNDERSTOOD is not RETAINED
  • What is RETAINED is not IMPLEMENTED

7
  • ASK QUESTIONS ANYTIME
  • During or after lecture

8
INTRODUCTION
9
(No Transcript)
10
(No Transcript)
11
(No Transcript)
12
(No Transcript)
13
Fairy Ring Mushrooms
14
What is Mycology?
15
Mycology is the study of
  • Beer
  • Wine
  • Bread
  • Cheese
  • Gourmet mushrooms
  • Environmental toxins
  • Biodegradation
  • Disease

16
(No Transcript)
17
(No Transcript)
18
(No Transcript)
19
(No Transcript)
20

21
(No Transcript)
22
(No Transcript)
23
BIOREMEDIATION
  • Clean up oil spills
  • Remove cyanide in mining operations
  • Neutralize dioxins and pesticides
  • Produce organic acids, sugars
  • Manufacture other commercial products

24
(No Transcript)
25
A. Classification
26
What is a Fungus ?
  • Eukaryotic a true nucleus
  • Do not contain chlorophyll
  • Have cell walls
  • Produce filamentous structures
  • Produce spores

27
Species of Fungi
  • 100,000 200,000 species
  • About 300 pathogenic for man

28
Kingdom Fungi Eukaryocytes
  • Ascomycota
  • Basidiomycota
  • Zygomycota
  • Mitosporic Fungi
  • (Fungi Imperfecti)

29
 
30
 
31
SIZE COMPARISON OF PATHOGENS
32
Actinomyces(True Bacteria)
  • Tradition
  • Clinical infection resembles mycoses
  • Actinomyces grow on mycotic media
  • Actinomyces grow slowly (24-48 h)
  • Gross colonies resemble fungi
  • (rough,heaped, short aerial filaments)
  • Resemble mycelia microscopically, with branched
    mycelia in tissue and smears.

33
HANDOUT
  • Page 2

34
What is Medical Mycology ?
35
MYCOTIC DISEASES(Four Types)
  • Hypersensitivity
  • Allergy
  • Mycotoxicosis
  • Production of toxin
  • Mycetismus (mushroom poisoning)
  • Pre-formed toxin
  • Infection

36
Hypersensitivity
  • FARMERS LUNG Moldy hay
  • MALT WORKERS DISEASE Moldy barley
  • CHEESE WASHERS LUNG Moldy cheese
  • WOOD TRIMMERS DISEASE Moldy wood

37
(No Transcript)
38
PATHOGENIC FUNGI
  • NORMAL HOST
  • Systemic pathogens - 25 species
  • Cutaneous pathogens - 33 species
  • Subcutaneous pathogens - 10 species
  • IMMUNOCOMPROMISED HOST
  • Opportunistic fungi - 300 species

39
PARASITIC STATE
  • Increased metabolic state
  • Modified metabolic pathways
  • Modified cell wall structure
  • Carbohydrate content
  • Lipid structure
  • RNA aggregates

40
PATHOGENICITY OF FUNGI
  • Thermotolerance
  • Ability to survive in tissue environment
  • Ability to withstand host defenses

41
REVIVED INTEREST IN MYCOLOGY
  • Increased frequency of mycotic diseases
  • Increased awareness by physicians
  • Better trained laboratory personnel
  • More invasive procedures used on patients
  • Increased use of immunosuppressive drugs
  • Increase in immunosuppressive disease
  • 7. Better laboratory diagnostic tools

42
(No Transcript)
43
B. MORPHOLOGY
44
MORPHOLGY
  • Yeasts
  • Hyphae (filamentous fungi, mycelium)
  • Septate
  • Coenocytic (non-septate)
  • Dimorphic
  • Yeast
  • Mycelium

45
(No Transcript)
46
(No Transcript)
47
(No Transcript)
48
Dimorphic Fungi
  • Yeast Form
  • Parasitic form
  • Tissue form
  • Cultured at 37 C
  • Mycelial Form
  • Saprophytic form
  • Cultured at 25 C

49
SPORES
  • SEXUAL
  • ASEXUAL
  • Arthrospore
  • Blastospore
  • Chamydospore
  • Conidia
  • Microconidia
  • Macroconidia

50

51
(No Transcript)
52
(No Transcript)
53
By their fruits ye shall know them
  • Mathew 720

54
(No Transcript)
55
EPIDEMIOLOGY
  • PAGE 3

56
  • MOST MYCOTIC AGENTS
  • ARE SOIL SAPRPHYTES

57
ECOLOGICAL ASSOCIATION
  • PATHOGEN HUMAN SOIL
  • _________________________________________
  • Coccidioides immitis 1900 1932
  • Histoplasma capsulatum 1934 1949
  • Cryptococcus neoformans 1894 1951

Blastomyces dermatitidis 1898 1964
58
Mycotic Diseases Are NOTContagious
59
(No Transcript)
60
ESTABLISHMENT OF INFECTION WITH A MYCOTIC AGENT
DEPENDS ON
  • Inoculum size
  • Resistance of the host

61
(No Transcript)
62
THE CLINICIAN MUST DISTINGUISH BETWEEN
  • COLONIZATION
  • FUNGEMIA
  • INFECTION

63
PORTAL OF ENTRY
MOUTH
RESPIRATORY TRACT
EYE
  • SKIN
  • HAIR
  • NAILS
  • RESPIRATORY TRACT
  • GASTROINTESTINAL TRACT
  • URINARY TRACT

SKIN
UROGENITAL TRACT
ANUS
64
COLONIZATION
MOUTH
RESPIRATORY TRACT
EYE
Multiplication of an organism at a given site
without harm to the host
SKIN
UROGENITAL TRACT
ANUS
65
INFECTION
MOUTH
RESPIRATORY TRACT
EYE
Invasion and multiplication of organisms in body
tissue resulting in local cellular injury.
SKIN
UROGENITAL TRACT
ANUS
66
GEOGRAPHIC DISTRIBUTION
  • The present ease and frequency of world-wide
    travel make it more likely that physicians in the
    United States will be confronted with a variety
    of unfamiliar mycoses acquired in distant parts
    of the country or of the world.

67
Endemic Mycoses
  • Those fungus infections with a limited geographic
    distribution. They are all caused by dimorphic
    fungi

68
PATIENT HISTORY
  • Medical
  • Travel
  • Occupation
  • Avocation

69
(No Transcript)
70
(No Transcript)
71
D. DIAGNOSIS
72
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA
probes
73
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA
probes
74
DIRECT MICROSCOPIC OBSERVATION
  • 10 KOH
  • Gentle Heat

75
(No Transcript)
76
KOH Wet Mount
77
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probes
78
SKIN TESTING(DERMAL HYPERSENSTIVITY)
  • Use is limited to
  • Determine cellular defense mechanisms
  • Epidemiologic studies

79
(No Transcript)
80
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probes
81
FUNGI ARE POOR ANTIGENS
82
FUNGAL SEROLOGYANTIBODIES
  • Latex Agglutination IgM
  • Immunodiffusion IgG
  • EIA IgG IgM
  • Complement Fixation IgG

83
(No Transcript)
84
Most serological tests for fungi measure
antibody. Newer tests to measure antigen are now
being developed
  • ANTIGEN DETECTION PRESENTLY AVAILABLE
  • Cryptococcosis
  • Histoplasmosis
  • Aspergillosis

85
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probes
86
DIRECT FLUORESCENT ANTIBODYCAN BE APPLIED TO
  • HISTOLOGIC SECTIONS
  • CULTURE
  • Viable organisms
  • Non-viable organisms

87
(No Transcript)
88
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probe
89
INFLAMMATORY REACTION
  • Normal host
  • Pyogenic
  • Granulomatous
  • Immunodeficient host
  • Necrosis

90
Polymorphic Nuclear Leukocytes
91
Giant Cell
92
GMS
93
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probes
94
ISOLATION MEDIA
  • SABOURAUD DEXTROSE AGAR
  • (pH 5.6)
  • Plain
  • With antibiotics
  • With cycloheximide

95
INCUBATION TEMPERATURE
  • 37 C - Body temperature
  • 25 C - Room temperature

96
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probes
97
DNA Probes
  • Rapid (1-2 Hours)
  • Species specific
  • Expensive

98
E. TREATMENT
99
THERAPY
  • Because they are eukaryotic, fungi are
    biochemically similar to the human host.
    Therefore it is difficult to develop
    chemotherapeutic agents that will destroy the
    invading fungus without harming the patient.

100
A BASIC TENET OF PATHOLGY
  • A CAUSE OF IRREVERSIBLE CELL INJURY IS CELL
    MEMBRANE DAMAGE.

101
IN FUNGAL THERAPY
  • We attempt to induce cell injury by causing
    the cell membrane of the fungus to become
    permeable.

102
PROBLEM
  • Finding an agent that will selectively injure
    fungal cell walls without damaging the host cell.

103
ALL EUKARYOTIC CELLS CONTAIN STEROLS
  • Mammalian cells cholesterol
  • Fungal cells - ergosterol

104
(No Transcript)
105
PRIMARY ANTI-FUNGAL AGENTS
  • Polyene derivatives
  • Amphotericin B
  • Nystatin
  • Azoles
  • Ketoconazole
  • Fluconazole
  • Itraconazole
  • Voriconazole
  • Posaconazole

106
AMPHOTERICIN BMechanism of Action
  • Amphotericin B binds to sterols
  • Ergosterol is a constituent of the fungal cell
    wall
  • AMB has a greater avidity for ergosterol than for
    the cholesterol in the human cell wall
  • Binding to the fungal cell wall alters the
    permeability and the intracellular contents leak

107
AMPHOTERICIN BDisadvantages
  • Intravenous administration
  • Thrombophlebitis
  • Nephrotoxic
  • Fever
  • Chills
  • Anemia
  • Long term administration

108
Azoles
  • There are a few rare serious side effects from
    Itraconazole and Fluconazole

109
PRIMARY ANTI-FUNGAL AGENTS
  • 3. Griseofulvin
  • 4. 5-fluorocytosine (5-FC)
  • 5. Allylamines
  • -Terbinafine (Lamasil)
  • 6. Echinocandins
  • - Caspofungin

110
Griseofulvin
  • A slow acting drug used for skin and nail
    infections. It accumulates in the stratum
    corneum and prevent hyphal penetration through
    these layers

111
5-fluorocytosine(5-FC)
  • Interferes With RNA Synthesis

112
MECHANISMS OF ACTION
  • Polyenes
  • Azoles
  • Griseofulvin
  • 5 - FC
  • Ergosterol in cell membrane
  • Interfere with ergosterol synthesis
  • Forms a barrier to fungal growth
  • Inhibits RNA synthesis

113
(No Transcript)
114
(No Transcript)
115
F. Clinical Classification of Mycoses
  • Cutaneous
  • Subcutaneous
  • Systemic
  • Opportunistic

116
Cutaneous Mycoses
  • Skin, hair and nails
  • Rarely invade deeper tissue
  • Dermatophytes

117
Subcutaneous Mycoses
  • Confined to subcutaneous tissue and rarely spread
    systemically. The causative agents are soil
    organisms introduced into the extremities by
    trauma

118
Systemic Mycoses
  • Involve skin and deep viscera
  • May become widely disseminated
  • Predilection for specific organs

119
OPPORTUNISTIC FUNGI
  • Ubiquitous saprophytes and occasional pathogens
    that invade the tissues of those patients who
    have
  • Predisposing diseases
  • Diabetes, cancer, leukemia, etc.
  • Predisposing conditions
  • Agammaglobulinemia, steroid or
    antibiotic therapy.

120
Medical Mycology Iceberg
121
THE ESSENTIAL ELEMENT OF DIAGNOSIS IS
  • A HIGH INDEX OF SUSPICION !

122
End of Introduction
About PowerShow.com